Link To Anti-SARS-CoV-2 Monoclonal Antibodies. Last Updated: August 4, 2021 from the NIH.

In this post I link to Anti-SARS-CoV-2 Monoclonal Antibodies. Last Updated: August 4, 2021 from the NIH.

Note: There is only one excerpt because I reviewed the complete resource. And when I re-review it, I will again review the complete resource.

What follows is from the above resource.

The SARS-CoV-2 genome encodes four major structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), as well as nonstructural and accessory proteins. The spike protein is further divided into two subunits, S1 and S2, that mediate host cell attachment and invasion. Through its receptor-binding domain (RBD), S1 attaches to angiotensin-converting enzyme 2 (ACE2) on the host cell; this initiates a conformational change in S2 that results in virus-host cell membrane fusion and viral entry.1 Monoclonal antibodies that target the spike protein have been shown to have a clinical benefit in treating SARS-CoV-2 infection (as discussed below). Preliminary data suggest that monoclonal antibodies may play a role in preventing SARS-CoV-2 infection in household contacts of infected patients2 and during skilled nursing and assisted living facility outbreaks.3

This entry was posted in COVID-19, COVID-19 Treatment, COVID-19 Treatment Trials, Infectious Diseases. Bookmark the permalink.